KPS Subsidiary BigThink Secures Asian Distribution Rights for Oral Symptom Treatment Aid 'MucosaMin' for Cancer Patients

Exclusive Contract with Italian Pharmaceutical Company Professional Dietetics
Exclusive Sales Rights in Korea and Japan... Priority Negotiation Rights in 7 Countries Including Singapore and Hong Kong
"Korea's First Oral Mucositis and Dryness Simultaneous Prevention and Treatment Supplement"

[Asia Economy Reporter Jang Hyowon] KPS subsidiary BigThink Therapeutics has secured the Asian distribution rights for 'Mucosamin,' an oral liquid formulation that helps prevent and treat oral mucositis caused by cancer treatments such as radiation and chemotherapy. This supplement is effective not only for oral mucositis but also for dry mouth.

On the 18th, BigThink announced that it had signed an Asian distribution rights contract with Italian amino acid specialist pharmaceutical company PDI (Professional Dietetics International S.r.l.) for a total of five products, including Mucosamin Oral Spray and Mouthwash.

Through this contract, BigThink acquired exclusive sales rights in Korea and Japan, and priority negotiation rights for seven countries including Malaysia, Hong Kong, Singapore, Indonesia, and the Philippines.

A BigThink official explained, "Among the approximately 140,000 cancer patients in Korea who undergo chemotherapy, radiation therapy, or BMT (bone marrow transplantation) annually, about 40% (around 58,300) suffer from oral mucositis. Additionally, about 20,000 patients with the autoimmune disease Sj?gren's syndrome suffer from dry mouth. Furthermore, patients with burning mouth syndrome, which frequently occurs in middle-aged women after menopause, also experience dry mouth."

Regarding Mucosamin, since it is a so-called customized treatment option for these patients, BigThink plans to sell it directly in Korea and enter other countries sequentially through partnering agreements.

Mucosamin is currently approved and sold in the European Union (EU), Israel, Jordan, Morocco, Iran, Vietnam, Nepal, and other countries, while simultaneous approval reviews are underway for global market entry in Australia, New Zealand, Canada, Egypt, Turkey, and others.

According to PDI, Mucosamin prevents cell damage through the antioxidant action of its main ingredient, sodium hyaluronate, and physically forms a protective barrier to aid wound healing. Additionally, the combination of amino acids (Glycine, L-Proline, L-Leucine, L-Lysine HCl, etc.), which are collagen precursors, helps recover mucosal ulcers and protects fibroblasts.

Kim Sungcheol, CEO of BigThink, said, "In April, we acquired exclusive domestic commercialization rights for Neratinib, an extended therapy drug for HER2-positive early breast cancer patients, from Puma Biotechnology, a Nasdaq-listed company in the U.S. We will continue to add various anticancer pipelines to create synergistic effects."